Cargando…

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial

IMPORTANCE: Dupilumab subcutaneous injection is approved for treating moderate-to-severe atopic dermatitis (AD) in adolescents, but there has been too little research on an efficacious systemic oral treatment with a favorable benefit-risk profile for adolescents with moderate-to-severe AD. OBJECTIVE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eichenfield, Lawrence F., Flohr, Carsten, Sidbury, Robert, Siegfried, Elaine, Szalai, Zsuzsanna, Galus, Ryszard, Yao, Zhirong, Takahashi, Hidetoshi, Barbarot, Sébastien, Feeney, Claire, Zhang, Fan, DiBonaventura, Marco, Rojo, Ricardo, Valdez, Hernan, Chan, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374743/ https://www.ncbi.nlm.nih.gov/pubmed/34406366 http://dx.doi.org/10.1001/jamadermatol.2021.2830

Ejemplares similares

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021)

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021)

Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
por: Ständer, Sonja, et al.
Publicado: (2022)

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
por: Alexis, Andrew, et al.
Publicado: (2022)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
por: Simpson, Eric L., et al.
Publicado: (2023)

Impact of Oral Abrocitinib Monotherapy on Patient-Reported Symptoms and Quality of Life in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis: A Pooled Analysis of Patient-Reported Outcomes
por: Silverberg, Jonathan I., et al.
Publicado: (2021)

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies
por: Kim, Brian S., et al.
Publicado: (2021)

High threshold efficacy responses in moderate‐to‐severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents
por: Ständer, S., et al.
Publicado: (2022)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023)

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
por: Simpson, Eric L., et al.
Publicado: (2021)

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
por: Gooderham, Melinda J., et al.
Publicado: (2022)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
por: Zhao, Jiahui, et al.
Publicado: (2022)

Efficacy of abrocitinib for atopic dermatitis: a meta-analysis of randomized controlled trials
por: Zhang, Daojun, et al.
Publicado: (2021)

Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Patient perspectives of atopic dermatitis: comparative analysis of terminology in social media and scientific literature, identified by a systematic literature review
por: Silverberg, J.I., et al.
Publicado: (2022)

Abrocitinib: First Approval
por: Deeks, Emma D., et al.
Publicado: (2021)

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
por: Li, Ling, et al.
Publicado: (2023)

Jade,
por: Palmer, Jock Pegler
Publicado: (1967)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Correction to: Abrocitinib: First Approval
por: Deeks, Emma D., et al.
Publicado: (2022)

Advances in understanding and managing atopic dermatitis
por: Barton, Michael, et al.
Publicado: (2015)

The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
por: Napolitano, Maddalena, et al.
Publicado: (2021)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
por: Wang, Junqiao, et al.
Publicado: (2022)

DESY: Physics with JADE
Publicado: (1979)

Rutherford: Preparing JADE
Publicado: (1978)

Pulir el jade
por: Suárez Caamal, Ramón Iván
Publicado: (1992)

Corazón de jade
por: Clevit, Sofía
Publicado: (2013)

EXHIBITION - Jade Kempter
por: Staff Association
Publicado: (2022)

Fast tensorial JADE
por: Virta, Joni, et al.
Publicado: (2020)

Costs and Treatment Patterns Among Patients with Atopic Dermatitis Using Advanced Therapies in the United States: Analysis of a Retrospective Claims Database
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Precolumbian jade : new geological and cultural interpretations

TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries
por: Vermeulen, F.M., et al.
Publicado: (2019)

Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Fadlalmola, Hammad Ali, et al.
Publicado: (2021)

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Gao, Qin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oai3en0fou42t57vv5vp5nhh96